The same study also found that RAD51C silencing was associated with sensitivity to PARP inhibitors in ovarian cancer [142], confirming that other members of the FA/HR pathway may also have utility as patient stratification biomarkers. This evidence concerns the gene RAD51C and ovarian cancer.